Toxicity after Intensity-Modulated, Image-Guided Radiotherapy for Prostate Cancer
- 30 September 2010
- journal article
- research article
- Published by Springer Nature in Strahlentherapie und Onkologie
- Vol. 186 (10) , 535-543
Abstract
To evaluate toxicity after dose-escalated radiotherapy for prostate cancer using intensity-modulated treatment planning (IMRT) and image-guided treatment (IGRT) delivery.Keywords
This publication has 53 references indexed in Scilit:
- A Randomized Trial Comparing Hypofractionated and Conventionally Fractionated Three-Dimensional External-Beam Radiotherapy for Localized Prostate AdenocarcinomaStrahlentherapie und Onkologie, 2009
- Acute and late toxicity in prostate cancer patients treated by dose escalated intensity modulated radiation therapy and organ trackingRadiation Oncology, 2008
- High-dose intensity-modulated radiotherapy for prostate cancer using daily fiducial marker-based position verification: acute and late toxicity in 331 patientsRadiation Oncology, 2008
- Does Intensity Modulated Radiation Therapy (IMRT) prevent additional toxicity of treating the pelvic lymph nodes compared to treatment of the prostate only?Radiation Oncology, 2008
- Acute toxicity of whole-pelvis IMRT in 87 patients with localized prostate cancerActa Oncologica, 2008
- Is There a Role for Pelvic Irradiation in Localized Prostate Adenocarcinoma? Preliminary Results of GETUG-01Journal of Clinical Oncology, 2007
- An Update of the Phase III Trial Comparing Whole Pelvic to Prostate Only Radiotherapy and Neoadjuvant to Adjuvant Total Androgen Suppression: Updated Analysis of RTOG 94-13, With Emphasis on Unexpected Hormone/Radiation InteractionsInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2007
- Increased Risk of Biochemical and Clinical Failure for Prostate Patients with a Large Rectum at Radiotherapy Planning: Results from the Dutch Trial of 68 GY Versus 78 GyInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2007
- Patient-reported acute gastrointestinal toxicity in men receiving 3-dimensional conformal radiation therapy for prostate cancer with or without neoadjuvant androgen suppression therapyUrologic Oncology: Seminars and Original Investigations, 2005
- Phase III Trial Comparing Whole-Pelvic Versus Prostate-Only Radiotherapy and Neoadjuvant Versus Adjuvant Combined Androgen Suppression: Radiation Therapy Oncology Group 9413Journal of Clinical Oncology, 2003